Muraglitazar for type 2 diabetes and associated lipid abnormalities - horizon scanning review
NHSC
Record ID 32005000234
English
Authors' objectives:
This study aims to assess the effectiveness of muraglitazar for type 2 diabetes and associated lipid abnormalities.
Authors' recommendations:
Muraglitazar (BMS 298585) is an oral dual (alpha- plus gamma-) peroxisome proliferator-activated receptor (PPAR) agonist in phase III clinical trials as an alternative to existing treatments for type 2 diabetes and associated lipid abnormalities. The company plan to publish results from ongoing phase III trials in 2005. Unpublished phase III and published phase II trials report that muraglitazar demonstrated significant glucose lowering properties as measured by reductions in HbA1c levels, reductions in triglycerides and increases in high-density lipoprotein cholesterol (HDL-C) levels compared with placebo.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Lipids
- Diabetes Mellitus, Type 2
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.